Pemafibrate is a highly selective PPARα modulator, and treatment with pemafibrate reduces serum triglycerides and increases high density lipoproteins (HDL) cholesterol in patients with dyslipidemia and metabolic diseases without deleterious side effects (Yamashita et al. 2020). Here, PPARA is linked to metabolic disease.